- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Forest Laboratories Inc. (FRX)
by latest | most commented
-
Healthcare: Branded Pharma Out, Diagnostics / Generics In
-
Forest Labs: Positive Top-Line Data on Ceftaroline
-
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch
-
Forest Labs: Concerned About Pipeline
-
S&P 500's Top Decile Economic Margin Companies
-
30 Attractive Companies Under $30: Fidelity's Low Priced Stock Fund Part II
-
Sell in May and Go Away? No Way
-
Cypress Bioscience: Investing in Pain
-
Top Ten S&P 500 Value Score Stocks
-
Pharmaceutical Stocks Remain a Buy
-
20 Stocks with High Net Cash
-
FDA, Clinical Trial Calendar Updates: Actelion, Merck Discontinue Partnership
-
Rentec Ratchets Up Positions in Q408
-
Thursday Options Update: FRX, CSX, RIMM & BIIB
-
The S&P 500's Strongest Balance Sheets
-
Pharma Investments Are Starting to Pay Off
-
Updates to FDA and Clinical Trial Calendars
-
Biopharma: Instead of M&A, Think P&A
-
Testing Benjamin Graham's Investment Criteria
-
What We View as Bruce Berkowitz's Best Holdings
-
Bullish Thesis for Biotech Remains Intact
-
Forest Laboratories: Perhaps the Next Consolidator?
-
Trading FDA Decisions: Cypress Bioscience Soars, A Trio of Buys
-
Ben Graham Approach to Investing Outperforms the Markets
-
Companies in Shape, and Looking Good...
-
Stocks Affected by FDA Calendar of Expected Decision Dates
-
Hedge Fund Portfolio Tracking: Renaissance Technologies (Jim Simons), Q3 2008
-
9 Possible Pharma Deals for 2009
-
4 Drug Stocks Trading Above Moving Averages
-
Five Healthcare Stocks Positioned for a Happy New Year
-
Updated FDA Calendar: Cypress Bioscience Looks Like a Buy
-
Cytori Therapeutics and Cypress Bio: Two Buys Based on Positive Trial Results
-
Sell Risk, Buy Pharma
-
What Are Some of the Best Hedge Fund Managers Doing?
-
Berkowitz, Rodriguez and Pabrai: Examining Q3 Filings
-
Recessionary Equity Strategies: Having It All
-
Backlog of Decisions Is Building at the FDA
-
Six Healthcare Stocks at Sale Prices
-
Recessionary Equity Strategies: Flight to Quality
-
FDA Action Before Year End
-
Options Trader: Outlook for a Testy Tuesday